

From: OC GCP Questions
To: [REDACTED]
Subject: Risk Based Remote Monitoring
Date: Thursday, June 08, 2017 6:56:00 AM
Attachments: [REDACTED]

Good morning --

<https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM269919.pdf>

Please see FDA's guidance document on a Risk Based Approach to Monitoring (above). It discusses documentation throughout the document.

Kind regards,

Doreen M. Kezer, MSN
Senior Health Policy Analyst
Office of Good Clinical Practice
Office of the Commissioner, FDA



This communication does not constitute a written advisory opinion under 21 CFR 10.85, but rather is an informal communication under 21 CFR 10.85(k) which represents the best judgment of the employee providing it. This information does not necessarily represent the formal position of FDA, and does not bind or otherwise obligate or commit the agency to the views expressed.

From: [REDACTED]
Sent: Wednesday, June 07, 2017 6:55 PM
To: OC GCP Questions
Subject: Risk Based Remote Monitoring

Can you please provide the FDA expectations of appropriate documentation to be present in the site file where the Sponsor elects to conduct remote monitoring rather than a physical visit. I currently have a Sponsor who thinks the Site Visit Log should be documented when a remote monitor visit is done but I disagree because the site is not being visited by me and I feel making an entry on the Site Visit Log would be confusing if not misleading to a reviewer. Please advise how FDA would recommend a remote monitoring visit to be documented. Thank you.

[REDACTED]